Eli Lilly Will Provide Early Access to A Next-Generation Obesity Medication

Eli Lilly (LLY.N) announced on Monday that it would grant early access to its experimental obesity medication, retatrutide, to a select group of patients prior to its U.S. FDA approval.

According to a business representative, “we think it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA’s guidance, for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial.”

According to the spokesman, Lilly has developed an enhanced access program “that does that and are actively reviewing requests from health care providers.”

Patients must be at least 18 years of age or older, have at least two significant or potentially fatal obesity-related problems for which they are getting treatment, and have refractory obesity despite tolerating the highest authorized dose of obesity therapy.

Additionally, patients should not be allowed to take part in any ongoing clinical trials for retatrutide or similar experimental treatments.

The extended access initiative was first reported by STAT News. A single 79-year-old patient was given privileged access to retatrutide by the business, according to earlier reports.

The three metabolic hormones that retatrutide is intended to target are glucagon, GIP, and GLP-1. GLP-1 and GIP are the objectives of the company’s current injectable obesity medication, Zepbound.

In July, Lilly reported that the highest weekly dose of retatrutide resulted in an average weight loss of 22.6% in an 80-week trial of patients with extreme obesity and established heart disease.

In the first quarter of the following year, the business intends to submit a request for FDA clearance for retatrutide.

Read Also : The Continuing Outbreak of Cyclosporiasis in Michigan Has Increased To 9,680 Cases